Oragenics Inc. [AMEX: OGEN] surged by $0.04 during the normal trading session on Friday and reaching a high of $1.10 during the day while it closed the day at $1.05. The company report on February 2, 2021 that SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Demonstrates Protective Immunity in Mice.
Data supports the Company’s approach to COVID-19 vaccine development.
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announces that the stabilized pre-fusion spike protein CoV-2 S-2P created by the National Institutes of Health (“NIH”) and licensed by the Company demonstrates protective immunity in immunized mice challenged with mouse-adapted SARS-CoV-2 virus.
Oragenics Inc. stock has also gained 14.75% of its value over the past 7 days. However, OGEN stock has inclined by 116.23% in the 3 months of the year. Over the past six months meanwhile, it has lost -1.87% and gained 133.85% year-on date.
The market cap for OGEN stock reached $92.70 million, with 91.77 million shares outstanding and 59.90 million shares in the current float. Compared to the average trading volume of 21.97M shares, OGEN reached a trading volume of 18596847 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Oragenics Inc. [OGEN]:
The Average True Range (ATR) for Oragenics Inc. is set at 0.13 The Price to Book ratio for the last quarter was 26.25, with the Price to Cash per share for the same quarter was set at 0.11.
OGEN stock trade performance evaluation
Oragenics Inc. [OGEN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 14.75. With this latest performance, OGEN shares gained by 69.35% in over the last four-week period, additionally sinking by -1.87% over the last 6 months – not to mention a rise of 98.38% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for OGEN stock in for the last two-week period is set at 65.52, with the RSI for the last a single of trading hit 66.18, and the three-weeks RSI is set at 64.83 for Oragenics Inc. [OGEN]. The present Moving Average for the last 50 days of trading for this stock 0.6594, while it was recorded at 0.9966 for the last single week of trading, and 0.6789 for the last 200 days.
Oragenics Inc. [OGEN]: An insightful look at the core fundamentals
Return on Total Capital for OGEN is now -80.98, given the latest momentum, and Return on Invested Capital for the company is -80.27. Return on Equity for this stock declined to -81.68, with Return on Assets sitting at -74.47. When it comes to the capital structure of this company, Oragenics Inc. [OGEN] has a Total Debt to Total Equity ratio set at 5.69. Additionally, OGEN Total Debt to Total Capital is recorded at 5.38, with Total Debt to Total Assets ending up at 4.96. Long-Term Debt to Equity for the company is recorded at 6.26, with the Long-Term Debt to Total Capital now at 3.68.
Reflecting on the efficiency of the workforce at the company, Oragenics Inc. [OGEN] managed to generate an average of -$2,223,715 per employee.Oragenics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.60 and a Current Ratio set at 9.60.
Earnings per share (EPS) analysis for Oragenics Inc. [OGEN] stock
With the latest financial reports released by the company, Oragenics Inc. posted -0.08/share EPS, while the average EPS was predicted by analysts to be reported at -0.1/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 20.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for OGEN.
Oragenics Inc. [OGEN]: Insider Ownership positions
There are presently around $10 million, or 7.20% of OGEN stock, in the hands of institutional investors. The top three institutional holders of OGEN stocks are: THIRD SECURITY, LLC with ownership of 4,612,166, which is approximately 0% of the company’s market cap and around 0.70% of the total institutional ownership; VANGUARD GROUP INC, holding 1,422,482 shares of the stock with an approximate value of $1.49 million in OGEN stocks shares; and SARA-BAY FINANCIAL, currently with $1.06 million in OGEN stock with ownership of nearly -23.518% of the company’s market capitalization.
Positions in Oragenics Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 11 institutional holders increased their position in Oragenics Inc. [AMEX:OGEN] by around 1,285,988 shares. Additionally, 9 investors decreased positions by around 442,191 shares, while 9 investors held positions by with 7,896,372 shares. The mentioned changes placed institutional holdings at 9,624,551 shares, according to the latest SEC report filing. OGEN stock had 6 new institutional investments in for a total of 368,029 shares, while 6 institutional investors sold positions of 102,790 shares during the same period.